KaloBios forms new management team with execs from Martin Shkreli’s Turing

KaloBios announced in November that it was winding down operations as it was running out of cash while trying to develop two potential cancer drugs.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.